Valley Fever Solutions
June 23, 2026
Theater 4
Type: Company Presentation
Focus Area:
Infectious Disease and Vaccines
Valley Fever Solutions is focused on a first-in-class antifungal that fills a gap in current therapy. This is promising against Aspergillus and Candida, each a $1.2B burden in just the US, highly fatal. Current advanced drugs that address these sell for >$600M. Our V-205 shows promise to be effective, and superior for many indications.
Our wedge project is a highly de-risked Phase-2-ready therapeutic already shown superior to current drugs to treat Valley Fever (VF, coccidioidomycosis). Our new V-205 formulation of nikkomycin Z (NikZ) increases potency ≥ 30-fold. NikZ prevents chitin formation, degrading fungal structure integrity, blocking proliferation, fungicidal. Chitin is found in all fungi, critical to many. V-204 cleared symptoms in several companion dogs with severe VF that had failed conventional therapy. V-204 should work equally well in humans.
We will seek approval for VF therapy (orphan designated) as we refine trials against broader indications.
Company HQ City:
Tucson
Company HQ State:
Arizona
Company HQ Country:
United States
Year Founded:
2007
Lead Product in Development:
Nikkomycin Z, new formulation
CEO
David J. Larwood PhD, JD, MBA
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
February 2028
What is your next catalyst (value inflection) update?
Phase 2A data
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}